We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,450.00 | 4,400.00 | 4,500.00 | 4,450.00 | 4,450.00 | 4,450.00 | 16,374 | 07:47:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 12.82M | 8.37M | 1.6071 | 27.69 | 231.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/3/2024 09:53 | Thx. Should have paid more attention in Maths at school :) | alter ego | |
26/3/2024 09:48 | Looks like R-squared, so it's just an indication of how well the straight line fits the underlying data. Shame it wasn't a bit more exponential-ish. | stepone68 | |
25/3/2024 23:00 | ?=9315. What value is ? Please | alter ego | |
25/3/2024 10:50 | Yes .... thats a hell of a price jump as well. Pity the troponon sales fell a little short. Added a few this morn. | janeann | |
25/3/2024 10:39 | I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price! | melody9999 | |
25/3/2024 07:32 | steady, points to competitive Alzheimer's environment with in-house mabs being developed by some IVD companies and alternative competition - market ought to be sufficiently large to support multiple competitors, temporary slowdown in troponin rate of adoption. | c3479z | |
13/3/2024 08:36 | Half year results due later this month. I expect another steady as she goes performance. Suet | suetballs | |
01/3/2024 10:30 | Hahaha, Blackhorse looking to invest his 'profits' from his investment in Watkins Jones WJG, I assume. Of course if he had been invested here - there would have been daily one line posts. | maddox | |
21/2/2024 15:36 | the filtered ebonised equine makes an unwelcome appearance. No doubt spots an opportunity to talk its own book as ever. | alter ego | |
21/2/2024 14:28 | Money moving to APH [LSE] , excellent growing health care company | blackhorse23 | |
21/2/2024 10:49 | Yes one heck of a rise since October last year. Suet | suetballs | |
21/2/2024 10:34 | Share price starting with a '5' now. Certainly feels like it is popular at the moment. | stepone68 | |
16/2/2024 16:07 | Something afoot? Suet | suetballs | |
16/2/2024 15:22 | maddox - all I can say is I can sell a shed load of these at 49.10 at present. someone still wants them 49.15 now!! | janeann | |
16/2/2024 11:31 | So, we're hitting new All Time High's despite the Director sale; 4848p as I post. Anyone with Level 2 able to shed some light on the activity? | maddox | |
12/2/2024 15:36 | Maddox... agree completey.... this has had plenty of strenght since Harrisons sale a could of weeks back. someone still wants them at 47.01! | janeann | |
12/2/2024 12:37 | BVXP are in the running to develop what has been described as the 'Holy Grail' of diagnostic testing - an early stage Alzheimer's test. BBC Radio 4 Today report on new Alzheimer's treatments. Mentions that there are about 28 dementia drugs in late stage development. Whilst the current two leading drugs show efficacy the promise is of better drugs being developed. The need for an early stage diagnostic test is clear in this report. Arguably, it's equally as important to have a simple early stage test as the drugs. | maddox | |
12/2/2024 12:16 | A Director's sale, if well handled, can work to enhance the share price - you sell sufficient shares to entice in a new Financial Investor - but not sell them as big a holding as they which to have. They then need to buy in the open market, creating demand and supporting the share price whilst they accumulate their desired holding. Can't say whether this is the case here but looks likely. | maddox | |
05/2/2024 09:37 | Looks like we are now back at an all time high - around the 4450 achieved 3 years ago, and there's been over £4 of divis since then as well. | stepone68 | |
29/1/2024 15:58 | Peter Harrison has sold £2.6 million worth of shares to a new institutional investor. | jurgenklopp | |
24/1/2024 09:15 | well researched 1c3479z. You're correct. I had conformation from Peter Harrison this morning. It does however, show the potential of the work being done by BVXP in this field. | alter ego | |
23/1/2024 16:42 | not convinced- the journal article refers to an ALZpath validated immunoassay, did ALZpath also provide the antibody? in any case, should this be validated, one expects the BVXP pTau 217 might have advantages over mouse monoclonals and be commercially in high demand from various diagnostics companies eg Roche etc with a long life cycle. | 1c3479z | |
23/1/2024 10:08 | Can't be certain but it sounds like a BVXP SMA. Sky news report today mentions " Measuring levels of a protein called p-tau217 in the blood...." "The study from Dr Nicholas Ashton at the University of Gothenburg, and colleagues, is published in the Jama Neurology journal." From BVXP Annual Report for year ended 30/6/23 "A leading blood biomarker for “A” is a phosphorylated form of tau called pTau217. A prototype assay from Gothenburg using an SMA has now been established which has performed well with frozen patient samples from a number of different cohorts." and "A novel blood-based prototype assay for neurodegeneration (N) using another Tau SMA has also been developed in Gothenburg. This work clearly supports the potential utility of this blood test and further work is ongoing in Gothenburg with further publications planned." | alter ego | |
23/1/2024 07:42 | Is it definitely Bioventix's study being referred to? https://www.ft.com/c | zebediah |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions